HR. 1843In Committee
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
Requires the FDA to increase transparency in generic drug applications by telling applicants whether a drug matches the listed brand-name drug and why it does not if it differs
Plain-English overview
What this bill does
Requires the FDA to increase transparency in generic drug applications by telling applicants whether a drug matches the listed brand-name drug and why it does not if it differs
Key points
- Require FDA applicant notifications
- Direct FDA guidance updates
Current status
Where it stands
Status
In Committee
Latest action
2025-03-05 — Referred to the House Committee on Energy and Commerce.
Related context
Topics and policy areas
undefinedHealth